Journal Mobile Options
Table of Contents
Vol. 29, No. 3, 2011
Issue release date: April 2011
Fetal Diagn Ther 2011;29:208–215

Maternal Serum Adiponectin at 11–13 Weeks of Gestation in Preeclampsia

Nanda S. · Yu C.K.H. · Giurcaneanu L. · Akolekar R. · Nicolaides K.H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To determine whether the maternal serum levels of adiponectin in the first trimester of pregnancy are altered in cases that develop preeclampsia (PE) and whether the levels are related to pregnancy-associated plasma protein-A (PAPP-A) and uterine artery pulsatility index (PI). Methods: Serum adiponectin, PAPP-A and uterine artery PI were measured at 11–13 weeks in 90 cases that developed PE, including 30 that required delivery before 34 weeks (early PE) and 300 unaffected controls. The median adiponectin, PAPP-A and uterine artery PI multiple of the unaffected median (MoM) in the outcome groups were compared. Results: In both early PE and late PE, compared to controls, uterine artery PI MoM was increased (1.32 and 1.05 vs. 1.02) and PAPP-A MoM was decreased (0.61 and 0.84 vs. 1.00), whereas adiponectin MoM was increased in early PE but not in late PE (1.32 and 1.05 vs. 1.02). In the PE group, there was no significant association between adiponectin and PAPP-A or uterine artery PI. Serum adiponectin did not improve the performance of screening for PE provided by a combination of the maternal factors, uterine artery PI and serum PAPP-A. Conclusion: Serum adiponectin levels at 11–13 weeks are increased in women that develop early PE by a mechanism unrelated to impaired placentation.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:12152–12162.
  2. Mazaki-Tovi S, Kanety H, Sivan E: Adiponectin and human pregnancy. Curr Diab Rep 2005;5:278–281.
  3. Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697–10703.
  4. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin in obesity. Biochem Biophys Res Commun 1999;257:79–83.
  5. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595–1599.
  6. Caruso A, Ferrazzani S, De Carolis S, Lucchese A, Lanzone A, De Santis L, Paradisi G: Gestational hypertension but not pre-eclampsia is associated with insulin resistance syndrome characteristics. Hum Reprod 1999;14:219–223.
  7. Solomon CG, Graves SW, Greene MF, Seely EW: Glucose intolerance as a predictor of hypertension in pregnancy. Hypertension 1994;23:717–721.
  8. Kaaja R, Laivuori H, Laasko M, Tikkanen MJ, Ylikorkala O: Evidence of a state of increased insulin resistance in preeclampsia. Metabolism 1999;48:892–896.
  9. D’Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G: Adiponectin and insulin resistance in early- and late-onset preeclampsia. BJOG 2006;113:1264–1269.
  10. Odden N, Henriksen T, Holter E, Grete Skar A, Tjade T, Mørkrid L: Serum adiponectin concentration prior to clinical onset of preeclampsia. Hypertens Pregnancy 2006;25:129–142.
  11. Yu CKH, Smith GCS, Papageorghiou AT, Cacho AM, Nicolaides KH: An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low risk women. Am J Obstet Gynecol 2005;193:429–436.
  12. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH: Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of preeclampsia. Ultrasound Obstet Gynecol 2007;30:742–749.
  13. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH: First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009;33:23–33.
  14. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Lancet 1998;352:343–346.
  15. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH: Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin, and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618–624.
  16. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX–XIV.
  17. Akolekar R, Syngelaki A, Sarquis R, Wright D, Nicolides KH: Prediction of preeclampsia from biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011;31:66–74.
  18. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493–502.
  19. Mente A, Razak F, Blankenberg S, Vuksan V, Davis AD, Miller R, Teo K, Gerstein H, Sharma AM, Yusuf S, Anand SS: Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care 2010;33:1629–1634.
  20. Meilleur KG, Doumatey A, Huang H, Charles B, Chen G, Zhou J, Shriner D, Adeyemo A, Rotimi C: Circulating adiponectin is associated with obesity and serum lipids in West Africans. J Clin Endocrinol Metab 2010;95:3517–3521.
  21. Swarbrick MM, Havel PJ: Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008;6:87–102.
  22. Bergmann S, Siekmeier R: Influence of smoking and body weight on adipokines in middle aged women. Eur J Med Res 2009;14:21–26.

    External Resources

  23. Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, Pineles BL, Gomez R, Edwin S, Mazor M, Espinoza J, Yoon BH, Hassan SS: Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. J Perinat Med 2007;35:522–531.
  24. Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B: Hypoadiponectinaemia in South Asian women during pregnancy: evidence of ethnic variation in adiponectin concentration. Diabet Med 2004;24:388–392.

    External Resources

  25. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, Hiramatsu Y: Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG 2010;117:314–320.
  26. D’Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM: Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. Obstet Gynecol 2005;106:340–344.
  27. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA: Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001;38:718–722.
  28. Roberts JM, Redman CW: Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447–1451.
  29. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH: Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003;361:1511–1517.
  30. Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ: Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Circ Res 2002;90:1274–1281.
  31. Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S, Post M, Caniggia I: Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005;90:4299–4308.
  32. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057–1063.
  33. Hattori Y, Suzuki M, Hattori S, Kasai K: Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003;46:1543–1549.
  34. Ramsay JE, Jamieson N, Greer IA, Sattar N: Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension 2003;42:891–894.
  35. Savvidou MD, Sotiriadis A, Kaihura C, Nicolaides KH, Sattar N: Circulating levels of adiponectin and leptin at 23–25 weeks of pregnancy in women with impaired placentation and in those with established fetal growth restriction. Clin Sci (Lond) 2008;115:219–224.
  36. Nien KJ, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, Pineles BL, Gomez R, Edwin S, Mazor M, Espinoza J, Yoon BH, Hassan SS: Adiponectin in severe preeclampsia. J Perinat Med 2007;35:503–512.
  37. Fasshauer M, Bluher M, Stumvoll M, Tonessen P, Faber R, Stepan H: Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol2007;66:434–439.
  38. Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA: Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. Am J Physiol Endocrinol Metab 2006;290:E326–E333.
  39. Hendler I, Blackweel SC, Mehta SH, Whitty JE, Russel E, Sorokin Y, Cotton DB: The levels of leptin, adiponectin, and resistin in normal weight, overweight, and obese pregnant women with and without preeclampsia. Am J Obstet Gynecol 2005;193:979–983.
  40. Kajantie E, Kaaja R, Ylikorkala O, Andersson S, Laivuori H: Adiponectin concentrations in maternal serum: elevated in preeclampsia but unrelated to insulin sensitivity. J Soc Gynecol Investig 2005;12:433–439.
  41. Naruse K, Yamasaki M, Umekage H, Sado T, Sakamoto Y, Morikawa H: Peripheral blood concentrations of adiponectin, an adipocyte-specific plasma protein, in normal pregnancy and preeclampsia. J Reprod Immunol 2005;65:65–75.
  42. O’Sullivan AJ, Kriketos AD, Martin A, Brown MA: Serum adiponectin levels in normal and hypertensive pregnancy. Hypertens Pregnancy 2006;25:193–203.
  43. Takemura Y, Osuga Y, Koga K, Tajima T, Hirota Y, Hirata T, Morimoto C, Harada M, Yano T, Taketani Y: Selective increase in high molecular weight adiponectin concentration in serum of women with preeclampsia. J Reprod Immunol 2007;73:60–65.
  44. Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, Cetin I, Cortelazzi R, Beck-Peccoz P, Spada A: Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin Endocrinol 2007;66:447–453.
  45. Ouyang Y, Chen H, Chen H: Reduced plasma adiponectin and elevated leptin in pre- eclampsia. Int J Gynaecol Obstet 2007;98:110–114.
  46. Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, Lossner U, Bluher M, Stumvoll M, Faber R, Stepan H: Circulating high-molecular-weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function. Eur J Endocrinol 2008;158:197–201.
  47. Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Gotsch F, Chaiworapongsa T, Than NG, Kim SK, Nhan-Chang CL, Jodicke C, Pacora P, Yeo L, Dong Z, Yoon BH, Hassan SS, Mittal P: Maternal serum adiponectin multimers in preeclampsia.J Perinat Med 2009;37:349–363.
  48. Herse F, Youpeng B, Staff AC, Yong-Meid J, Dechend R, Rong Z: Circulating and Uteroplacental adipocytokine concentrations in preeclampsia. Reprod Sci 2009;16:584–590.
  49. Avci I, Ozerkan K, Uncu G: Serum adiponectin levels increase in lean preeclamptic women. Prenat Diagn 2010;30:91–92.
  50. Mori T, Shinohara K, Wakatsuki A, Watanabe K, Fujimaki A: Adipocytokines and endothelial function in preeclamptic women. Hypertens Res 2010;33:250–254.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50